The 80+ population is accelerating, supply is tight, and two REITs
could benefit. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏



 

[Morning Watchlist]

_You are receiving this email because you are subscribed to BEHIND THE
MARKETS. If you no longer wish to receive these emails,
please unsubscribe
[[link removed]] here._

Prefer to view this content on our website? CLICK HERE.
[[link removed]]

-------------------------

ONE OF THE BEST WAYS TO INVEST IN AN AGING POPULATION — WITH YIELD

The U.S. is entering a demographic phase shift that investors tend to
underestimate until it’s already visible in earnings reports and
rent rolls.

The “headline” statistic is that the 65+ cohort is growing
steadily, but the more investable catalyst is the surge in the 80+
POPULATION—the age band where healthcare utilization climbs,
mobility declines, and the probability of needing structured senior
housing rises meaningfully. That wave is now close enough to touch:
the oldest Baby Boomers begin turning 80 in 2026, and multiple
industry trackers expect a sharp step-up in senior-housing demand as
that milestone cohort expands.

At the same time, supply is not keeping up. Senior-housing development
slowed dramatically coming out of the pandemic era, and higher
financing and construction costs have made new projects harder to
pencil. That imbalance—DEMAND RISING INTO CONSTRAINED SUPPLY—is
exactly the kind of setup that can translate into higher occupancy,
stronger pricing power, and better operating leverage for
well-positioned owners and operators.

Layer on top a second structural pressure: the care economy is
strained. The U.S. faces persistent shortages across healthcare labor
and caregiving—whether you measure it through home-care worker
availability or physician supply projections. In practical terms,
shortages tend to shift more families toward professionally managed
care settings (or at least toward organizations with scale and
staffing infrastructure), which can support facility demand over time.

-------------------------

WHY HEALTHCARE AND SENIOR-HOUSING REITS MATTER RIGHT NOW

For income investors, the appeal is straightforward: REITs can combine
CASH DISTRIBUTIONS with exposure to a long-duration demographic trend.
But not all healthcare REIT exposure is created equal.

Broadly, the most attractive setups typically have some mix of:

*
SENIOR HOUSING EXPOSURE (where demand is tied to aging dynamics),

*
OPERATIONAL UPSIDE from improving occupancy and pricing,

*
DIVERSIFICATION across property types and operators (reducing
single-tenant or single-market risk),

*
And BALANCE SHEET FLEXIBILITY to fund acquisitions or renovations as
the cycle turns.

With that in mind, here are two yield-oriented ways to position for
the theme.

-------------------------

_RAD Intel_

$10K INVESTMENT IN NVIDIA COULD'VE MADE $2.5M
[[link removed]]

Imagine investing $10K into Nvidia a decade ago—today that’s
$1.25M. That's the power of getting in early on the right startup.
 We think RAD Intel is next.  They’re applying AI to solve a
problem every marketer faces: how to reach the right audience with the
right message. Backed by Adobe, multiple Fidelity funds, and already
in use by Fortune 1000s - this company’s valuation has soared 5000%+
in just 4 years*.

RAD Intel’s software is built for AI 2.0: intelligent targeting that
powers real ROI. They’ve already reserved a Nasdaq ticker symbol,
$RADI and this is a rare opportunity to get in on a high-growth AI
software company at the ground floor.

The company is offering shares at just $0.85 right now.

Don’t let this be another “I wish I had…” moment. The
opportunity is now!

👉 LOCK IN $0.85 SHARES TODAY
[[link removed]]

*DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A+
offering and involves risk, including the possible loss of principal.
Please read the offering circular and related risks at
invest.radintel.ai. 

-------------------------

COMPANY: AMERICAN HEALTHCARE REIT (SYM: AHR)
SENIOR HOUSING + CLINICAL REAL ESTATE EXPOSURE

American Healthcare REIT provides diversified healthcare real estate
exposure, with meaningful linkage to the senior-housing demand cycle.
A key point for 2026 is that the company is already showing measurable
operating momentum: in its Q3 2025 results, the firm reported REVENUE
OF $572.9 MILLION (UP 9.4% YEAR OVER YEAR) and cited another quarter
of strong same-store NOI growth, with particularly robust performance
in senior-housing-related segments.

That matters because when a demographic theme turns “real,” it
typically shows up first in the boring numbers:

*
occupancy trends,

*
same-store NOI,

*
rent/revenue per occupied room,

*
and acquisition cap rates versus a company’s cost of capital.

On the calendar, American Healthcare REIT has a clear near-term
catalyst: the company has announced it will release Q4 2025 EARNINGS
ON THURSDAY, FEBRUARY 26, 2026 (AFTER MARKET CLOSE), followed by a
conference call the next day. Earnings events matter here because
senior housing is a narrative-driven space—guidance and forward
commentary on occupancy, pricing, and labor costs can move the stock.

INCOME ANGLE: AHR has been paying a quarterly dividend (recently $0.25
per share). Based on the current market price, that equates to a
low-single-digit yield profile—less “ultra-high yield,” more
“demographic growth + income.”

WHAT TO WATCH:

*
Occupancy and pricing power as the 80+ wave accelerates

*
Labor cost trends and staffing stability (a major swing factor for
margins)

*
Acquisition discipline and leverage as the cycle turns

-------------------------

_Med-X Inc._

DISRUPTING A $17B INDUSTRY — WITHOUT CHEMICALS
[[link removed]]

[med X]
[[link removed]]

Chemical pesticides are getting banned.
Consumers want safer alternatives.
Governments are forcing change.

MED-X ($MXRX) IS ALREADY THERE.

Its plant-based NATURE-CIDE® pesticides have beaten chemical brands
head-to-head in independent lab tests — without toxic risk.

With $6.4M IN SALES, placement at Amazon, Walmart & Kroger, and
expansion into 41 countries, Med-X is scaling fast ahead of its
planned Nasdaq listing.

Reserved Nasdaq Ticker: MXRX
Shares available at $4

👉 BECOME A SHAREHOLDER BEFORE THE NASDAQ PLANS UNFOLD
[[link removed]]

-------------------------

COMPANY: CARETRUST REIT (SYM: CTRE)
SKILLED NURSING + SENIOR LIVING LANDLORD WITH INCOME FOCUS

CareTrust is a different flavor of the theme: it is heavily tied to
skilled nursing and senior living assets, which can benefit from aging
demographics—but also carry unique reimbursement and operator risks.

Operationally, CareTrust’s reported Q3 2025 results showed
NORMALIZED FFO OF $0.45 PER DILUTED SHARE (up year over year) and
strong revenue performance (reported around $132.44 MILLION in that
quarter). For REIT investors, FFO is the lifeblood metric: it’s what
ultimately supports dividend capacity and balance sheet strength.

INCOME ANGLE: CTRE’s dividend profile is one of the reasons it tends
to show up on income investors’ radars. Recent dividend trackers
list an annualized dividend around $1.34 per share, implying a mid-3%
yield area at recent prices.

WHAT TO WATCH:

*
Tenant/operator health (especially if labor or reimbursement pressures
spike)

*
Policy headlines (Medicaid/Medicare sensitivity is real in parts of
the skilled nursing ecosystem)

*
Acquisition pace and cost of capital as rates and credit conditions
evolve

THE BIG PICTURE: WHY THE NEXT FEW YEARS COULD SURPRISE TO THE UPSIDE

The key reason this theme can work is not just “more older
people.” It’s TIMING + CONSTRAINTS:

*
THE AGE MIX IS SHIFTING TOWARD 80+, the point where demand for senior
facilities historically rises.

*
SUPPLY GROWTH HAS LAGGED, creating a scenario where operators can
regain pricing power as occupancy tightens.

*
CAREGIVING AND HEALTHCARE STAFFING REMAIN CONSTRAINED, nudging
families toward managed care solutions and putting a premium on scaled
platforms.

If those three forces stay in place, the “aging population trade”
stops being a slow-and-steady story and starts looking more like a
classic cycle: rising occupancy → rising NOI → improving cash flow
→ improving dividend durability (and potentially dividend growth).

-------------------------

_Huge Alerts_

BSEM: FROM PROFITABLE REGENERATIVE LEADER TO ADVANCED WOUND CARE
POWERHOUSE WITH A NASDAQ UPLISTING ON THE HORIZON.
[[link removed]]

BioStem Technologies (OTCQB: BSEM) continues to separate itself from
the small-cap MedTech pack with seven straight profitable quarters,
FDA-registered manufacturing, and clinically proven BioREtain®
technology that drives superior healing outcomes in diabetic foot
ulcers. 

The recent acquisition of BioTissue’s surgical and wound care
business adds $29 million in revenue, a national sales network, and
immediate access to hospital and surgical settings, creating a direct
path into acute and advanced wound care markets.

With early adoption reflected in 40% year-over-year unit growth, a
robust $300–$350 million market opportunity, and a potential Nasdaq
uplisting in mid-2026, BSEM is executing on every element of a
high-growth MedTech strategy. 

With a $25.50 price target from Zacks, BSEM stands out as a small-cap
MedTech name with significant upside potential, especially as it
prepares for a potential Nasdaq uplisting in 2026. Strong financial
discipline, expanding commercial reach, and validated clinical results
make BSEM a rare small-cap story to keep an eye on.

SEE HOW BSEM IS REDEFINING THE FUTURE OF ADVANCED AND ACUTE WOUND CARE
IN 2026 WHILE BUILDING SHAREHOLDER VALUE
[[link removed]]

-------------------------

_Are there any other REITs you've got your eye on right now? What
other sectors of the market are you currently interested in? Hit
"reply" to this email and let us know your thoughts!_

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that this is a paid advertisement for
Med-X's Regulation A+ Offering offering and we have received or expect
to receive compensation in connection with the disbursing this
communication for Med-X . The compensation could consist of $4,025.00
or more and was received/will be received from Investing Media
Solutions.

This communication should not be considered as an endorsement of Med-X
and we are not responsible for any errors or omissions in any
information provided about by or about Med-X.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 02/04/2026.

Behind the Markets
[[link removed]]

Unsubscribe
[[link removed]]

invisiblelink
[[link removed]]